Compare Ascendis Pharma A/S (ASND) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Grab Holdings Ltd. — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Grab Holdings Ltd. trades at $3.74 (market cap $14.97B). The key difference: Ascendis Pharma A/S and Grab Holdings Ltd. are close in size by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| ASND | GRAB | |
|---|---|---|
Market Cap | $16.78B | $14.97B |
Sector | Health | Technology |
52-Week High | $277.18 | $6.45 |
52-Week Low | $189.74 | $3.27 |
Enterprise Value | $17.15B | $10.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
